Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-131-3
CAS number: 7440-22-4
AgNP biodistribution in organs and blood:
The SP-ICP-MS method used to analyze dimensional distributions (nm) and concentration (particle/mL) of AgNPs in organs and blood was firstly validated by the measurements of stability, recovery and repeatability, inorder to guarantee that no aggregation/agglomeration or dissolution of particles was present in the different matrices after TMAH extraction.
Dose-response trend and comparable curves between sexes were present in AgNP biodistribution in blood, liver, kidney and spleen with higher AgNP concentration in female mice in blood and kidney, and in male mice in liver and spleen. In duodenum, no dose-response trend was present in both sexes.
Hepatic and duodenum cells of high dose treated male and female mouse showed no pathological ultrastructural changes in nuclei, cytosol and organelles, and cells from control. tissues were comparable with treated tissues. In liver, AgNPs were located either inside membrane bound structures or dispersed in the cytosol. In the intestinal cells, AgNPs were located insinde membrane bound structures or dispersed in cytosol along microvilli and the presence was comparable in treated and control mice. Both in liver and in duodenum, no AgNPs were detected in the nucleus. Both in liver and duodenum of female mice, AgNPs appeared to be more abundant and better distributed with well-defined membrane in comparison to the same tissues of male mice.
Liver and kidney biomarkers:
Liver serum biomarkers showed, in female mice, significantly reduced levels of GOT and GPT in low dose and mid-dose level, respectively. No statistical sisgnificance alterations were present in male mice. Kidney serum biomarkers showed, in male mice, significantly increased levels in high dose no effects were recorded in female mice.
Histopathological and histomorphometrical analysis:
No significant differences were present in liver, kidney, duodenum and spleen of AgNPs treated male and female mice compared to control.
This comet assay has been conducted according to the OECD 489 guideline and under GLP principle.
After 1week of acclimatization, mice were divided into 4 treatment groups. (5 mice/sex/group). CD1 mice (male and female) have been treated with 3 different doses (50, 150, 300 mg/kg bw/d) of AgNP-20nm during 3 consecutive days. The vehcile control group has been treated with distilled water and the positive control group (3 mice/sex) has been treated with MMS.
2 hours after the last treatment mice were sacrified and target tissues were analysed for DNA damage. General toxicity was assessed by kidney and liver biomarkers (GOT, GPT, CREA).
In conclusion, AgNP-20nm (up to 300 mg/kg bw/d) do not induce genotoxic damage (DNA damage) after 3 days of oral acute exposure of adult in male and female mice.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again